UT Southwestern completes phase 2 tirzepatide pilot in methamphetamine use disorder
The open-label study, begun February 2025, tested feasibility in patients with comorbid obesity taking tirzepatide for its approved weight indication.
PR
By Priya Raman · Science Reporter
Sep 28 08:00 ETSource: ClinicalTrials.gov
The wire
- 01NCT06745128, a phase 2 open-label pilot sponsored by University of Texas Southwestern Medical Center, is listed as completed; it started 3 February 2025.
- 02Incretin effects on substance use are an active off-label question clinicians are already fielding from patients.
- 03The registry entry gives no enrollment or results; open-label pilot designs cannot establish efficacy in methamphetamine use disorder.
From the source
Read at clinicaltrials.govTirzepatide for Obesity and Meth Use Disorder
NCT06745128 · PHASE2 · COMPLETED · Sponsor: University of Texas Southwestern Medical Center · Conditions: Obesity, Methamphetamine Use Disorder.
Source URL https://clinicaltrials.gov/study/NCT06745128
